Trevi Therapeutics, Inc. (TRVI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 41.37M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 8.06M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -59.56M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $41.37M | (m) | $8.06M | $-59.56M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $35.61M | (m) | $6.17M | $-52.77M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $33.48M | (m) | $5.18M | $-49.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $36.61M | (m) | $4.75M | $-51.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $37.75M | (m) | $4.33M | $-51.52M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $38.38M | (m) | $4.07M | $-51.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $39.38M | (m) | $3.59M | $-51.52M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $36.57M | (m) | $3.21M | $-48.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $31.67M | (m) | $2.91M | $-43.17M | $9.00K | (m) | (m) | -4797.00× | Reported |
| 2024-03-31 | $27.49M | (m) | $2.39M | $-38.27M | $161.00K | (m) | (m) | -237.68× | Reported |
| 2023-12-31 | $23.68M | (m) | $2.25M | $-33.92M | $391.00K | (m) | (m) | -86.76× | Reported |
| 2023-09-30 | $21.48M | (m) | $2.21M | $-31.65M | $661.00K | (m) | (m) | -47.88× | Reported |
| 2023-06-30 | $20.93M | (m) | $2.25M | $-31.01M | $950.00K | (m) | (m) | -32.64× | Reported |
| 2023-03-31 | $20.19M | (m) | $2.17M | $-30.45M | $1.09M | (m) | (m) | -27.88× | Reported |
| 2022-12-31 | $19.83M | (m) | $2.33M | $-29.91M | $1.16M | (m) | (m) | -25.72× | Reported |
| 2022-09-30 | $21.70M | (m) | $2.37M | $-31.52M | $1.20M | (m) | (m) | -26.31× | Reported |
| 2022-06-30 | $20.64M | (m) | $2.34M | $-30.07M | $1.21M | (m) | (m) | -24.87× | Reported |
| 2022-03-31 | $22.04M | (m) | $2.56M | $-31.41M | $1.21M | (m) | (m) | -25.96× | Reported |
| 2021-12-31 | $22.98M | (m) | $2.54M | $-32.48M | $1.20M | (m) | (m) | -27.02× | Reported |
| 2021-09-30 | $23.36M | (m) | $2.51M | $-33.40M | $1.20M | (m) | (m) | -27.81× | Reported |
| 2021-06-30 | $23.48M | (m) | $2.56M | $-33.69M | $1.05M | (m) | (m) | -32.21× | Reported |
| 2021-03-31 | $21.90M | (m) | $2.40M | $-31.94M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $22.33M | (m) | $2.42M | $-32.49M | $456.00K | (m) | (m) | -71.25× | Reported |
| 2020-09-30 | $20.59M | (m) | $2.28M | $-30.06M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $21.41M | (m) | $2.06M | $-30.47M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $22.02M | (m) | $1.71M | $-30.47M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $19.34M | (m) | $1.13M | $-26.64M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $14.07M | (m) | $496.00K | $-18.41M | $174.00K | (m) | (m) | -105.79× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |